Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

REGENXBIO Doses First Patient in RGX-111 Trial for Mucopolysaccharidosis Type I Treatment

americanpharmaceuticalreviewDecember 16, 2020

Tag: Regenxbio , RGX-111 , MPS I , gene therapy

PharmaSources Customer Service